Evidence map›Paper›PMID 42521312›Full record

ArticleBMJ open2026

BASTA trial: protocol for a randomised, double-blind, placebo-controlled, crossover trial investigating the effects of atorvastatin on bile acid diarrhoea.

Mads Bank Lynggaard, Sólvá Strøm Olsen, Julie Lyng Forman, Martin Lund Kårhus, Lise Lotte Gluud, Asger Bach Lund, Anne-Marie Ellegaard

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07042165 (Treatment of Bile Acid Diarrhoea With Atorvastatin), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07042165 phase4active not recruitingnot on this map

Treatment of Bile Acid Diarrhoea With Atorvastatin (BASTA): A Randomised, Double-Blind, Placebo-Controlled, Crossover, Investigator-Initiated Trial

TypeinterventionalSponsorAsger Lund, MDRan2025 to 2026Enrolled20ConditionsBile Acid Diarrhea, Bile Acid MalabsorptionArmsAtorvastatin, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mads Bank LynggaardCenter for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.ORCID 0000-0002-5663-0234
Sólvá Strøm OlsenCenter for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Julie Lyng FormanSection of Biostatistics, Department of Public Health, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Martin Lund KårhusCenter for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Lise Lotte GluudGastro Unit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.ORCID 0000-0002-9462-4468
Asger Bach LundCenter for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Anne-Marie EllegaardCenter for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark anne.marie.gade.ellegaard@regionh.dk.ORCID 0000-0002-4389-3908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBile acid diarrhoea (BAD) is a chronic disease with typical symptoms of daily watery stools with increased frequency and urgency. BAD arises due to pathologically high levels of bile acids in the colon, which may be due to impaired reabsorption or increased synthesis. Evidence indicates that atorvastatin administration suppresses bile acid synthesis in healthy individuals, likely due to reduced substrate availability. The Bile Acid diarrhoea STAtin Trial aims to investigate whether atorvastatin treatment reduces bile acid synthesis in patients with BAD and consequently alleviates BAD symptoms. METHODS AND ANALYSIS: 20 adults with moderate-to-severe BAD, assessed by the gold standard diagnostic test ETHICS AND DISSEMINATION: The study is approved by the Danish Medicines Agency and the Regional Scientific Ethics Committee of the Capital Region of Denmark (2025-521 856-47-00) and registered with the Danish Data Protection Agency (p-2024-17870). The study is monitored by the Capital Region of Denmark's Good Clinical Practice unit. All results will be disseminated at national and/or international scientific meetings and in peer-reviewed scientific journals. TRIAL REGISTRATION NUMBER: NCT07042165.

Indexed as

AtorvastatinBile Acids and SaltsDiarrheaHydroxymethylglutaryl-CoA Reductase InhibitorsAdultBiomarkersCholestenonesCross-Over StudiesDouble-Blind MethodHumansMaleRandomized Controlled Trials as Topic7 alpha-hydroxy-4-cholesten-3-oneAtorvastatinBile Acids and SaltsBiomarkersCholestenonesHydroxymethylglutaryl-CoA Reductase InhibitorsChronic DiseaseClinical TrialTreatment Outcome

Identifiers

PMID42521312
PMCPMC13423145

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.